Moving forward, further studies involving in vivo toxicity assessments, pharmacokinetics, and functional validation of molecular targets—particularly YAP/TAZ—will be critical to fully establish its translational potential in colorectal cancer therapy. The gene discussed is YAP1; the disease is colorectal cancer.